Business
Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its second quarter ended June 30, 2025, and provided a corporate update.
About this update from Innoviva, Inc.
[{"type":"text","content":"Entered into secured credit agreement with Innoviva for $15 million maturing in 2029","length":84,"tagName":"p","attribs":{}},{"type":"text","content":"Announced positive topline results from the Phase 1b/2a diSArm trial for AP-SA02","length":80,"tagName":"p","attribs":{}},{"type":"text","content":"LOS ANGELES, Aug. 12, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its second quarter ended June 30, 2025, and provided a corporate update.","length":472,"tagName":"p"},{"type":"image","alt":"Armata Pharmaceuticals Logo (PRNewsfoto/Armata Pharmaceuticals, Inc.)","displaySize":"","headline":null,"caption":"Armata Pharmaceuticals Logo (PRNewsfoto/Armata Pharmaceuticals, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":233,"url":"https://media.zenfs.com/en/prnewswire.com/7c5ae7fba5bf4523a1183526f430008d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bvnlEtALuiGK.3Dxno4EVg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQxMTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/7c5ae7fba5bf4523a1183526f430008d","width":400,"height":233}},"href":"https://mma.prnewswire.com/media/884786/Armata_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Second Quarter 2025 and Recent Developments: ","length":44,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"On August 11, 2025, entered into a secured credit agreement with Innoviva Strategic Opportunities LLC, a wholly owned subsidiary of Innoviva, Inc., Armata's largest shareholder, for a loan of $15.0 million that will mature on January 11, 2029","length":246,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Proceeds from the new financing transaction will be used to continue to advance development of Armata's lead Staphylococcus aureus ("S. aureus") therapeutic phage candidate, AP-SA02, a novel intravenously administered multi-phage therapeutic for the treatment of complicated S. aureus bacteremia","length":314,"tagName":"p"}]}],"tagName":"ul",...